Abcodia is a specialist company engaged in developing biomarkers for the early detection of cancer. Our mission is to help every individual lead a longer healthier life.
|Address:||The Network Building, 97 Tottenham Court Road, London|
|Membership type:||Professional Individual and Corporate < 5 (£50+VAT pa)|
Abcodia is a specialist company engaged in developing biomarkers for the early detection of cancer. The company has developed deep expertise in the methods and technology relevant to the discovery and validation of biomarkers that can be detected well before the symptomatic presentation of cancer. Through an exclusive commercial license to the UKCTOCS biobank, the company is able to use samples from this population cohort to develop a pipeline of diagnostic products for the early detection of a range of cancers. Abcodia has received investment from Albion Ventures and UCL Business.
Abcodia Ltd, a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, has announced the availability of the ROCA® Test for use by physicians in five US states: Arizona, Illinois, Massachusetts, New Jersey and Texas. The test is already being used in the UK by private clinics and will become available in additional US states throughout 2016.
3 December 2015Read in full
Abcodia today announced that it has signed a collaboration agreement with The University of Manchester to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
5 August 2015Read in full
Abcodia, a specialist company engaged in the development of tests for early detection of cancer, has announced the appointment of Mrs Nadia Altomare as President of North America.
27 May 2015Read in full
Abcodia, a specialist company engaged in the development of tests for the early detection of cancer, is to make ROCA® available as an innovative ovarian cancer screening test this year, on the back of new clinical data further indicating its high performance.
12 May 2015Read in full
Abcodia, a specialist company engaged in the development of tests for the early detection of cancer, with exclusive worldwide licence to the ovarian cancer screening test, ROCA®, has welcomed the publication of a major study that reaffirms its high performance.
5 May 2015Read in full
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research UK, Cancer Research Technology and Abcodia, a specialist company engaged in the validation of biomarkers for the early detection and screening of cancer.
10 December 2014Read in full
Abcodia's CEO Dr Julie Barnes is ranked among the UK's top inspirational women listed in the 50 Movers and Shakers in the BioBusiness 2014.
29 October 2014Read in full
Abcodia has announced an initiative to license access to serum samples from its unique longitudinal serum biobank for use in discovery and validation of biomarkers for haematological cancers. This unparalleled resource, believed to be the largest longitudinal collection of its kind, can substantially reduce the time to market and cost of R&D.
22 October 2014Read in full
Abcodia today announced that it has secured a grant from the European Commission’s Horizon 2020 programme to validate an algorithm-based test for the screening of individuals at high risk of pancreatic cancer. The test will be one of the first examples of a personalised screening diagnostic and aims to improve survival rates in this devastating disease.
18 September 2014Read in full